During the 2nd European CAR T Cell Meeting, Jennifer Specht presented data on the use of ROR1 targeted CAR T-cell therapy for chronic lymphocytic leukemia and solid tumors. The Lymphoma Hub reports a summary of the...
New prognostic model for survival in patients with R/R DLBCL
Summary of the new prognostic model for survival presented at ASH 2019 in patients with R/R DLBCL. The study aimed to evaluate clinical predictors of outcome at first relapse or progression...
Axi-cel for secondary CNS lymphoma
A retrospective analysis evaluating the efficacy and safety of axi-cel treatment in patients with secondary CNS lymphoma. The results were presented at the 61st American Society of Hematology (ASH) Annual Meeting &...
EMA extends the license indications for rituximab and venetoclax
The therapeutic potential of two lymphoma therapies has been broadened. The EMA has announced license extensions of rituximab and the combination of venetoclax with obinutuzumab.
"The Lymphoma Hub allows you to navigate the most relevant and up-to-date information in lymphoma and CLL. From recently published papers to on-site interviews, we aim to deliver valuable data to all physicians practicing hemato-oncology."